We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Comparison of Two Cognitive Batteries in People With Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00499044
Recruitment Status : Completed
First Posted : July 11, 2007
Last Update Posted : November 26, 2009
Information provided by:

Study Description
Brief Summary:

The investigators will compare the test-retest reliabilities of two cognitive batteries in people with schizophrenia: Cognitive Drug Research Computerized Cognitive Assessment System ("CDR") and MATRICS Consensus Cognitive Battery ("MCCB"). The investigators hypothesize that there will be a statistically significant difference in the test-retest reliabilities between MCCB and CDR. In addition, the investigators hypothesize that each of the two batteries will better measure certain areas of cognition. The investigators also hypothesize that scores from both batteries will correlate with quality of life scores, and that there will be a significant difference between the correlations of MCCB and CDR. The investigators hypothesize there will be a significant difference in patients' self-reported tolerability and satisfaction of the MATRICS versus CDR assessments. Lastly, the investigators hypothesize that there will be a significant difference in the MATRICS versus CDR batteries with respect to an administrator-rated score of practicality.

Approximately 32 subjects will enroll in the study. Following consent and eligibility screening (visit 1) and baseline clinical assessment and training in the use of the CDR battery (visit 2), subjects will be randomized into one of two groups for visits 3 and 4. One group will complete the CDR and then MCCB in visit 3, as well as the Tolerability Scale for each battery. The other group will complete the batteries in reverse order during visit 3. Each group will complete both batteries again in reverse order for visit 4. Randomization will be done in blocks of 2. After completion of every 4 subjects, study administrators will complete the Practicality Scale for each battery.

Condition or disease Intervention/treatment
Schizophrenia Schizoaffective Disorder Other: CDR Computerized Cognitive Assessment System Other: MATRICS Consensus Cognitive Battery

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: CDR Versus MATRICS Cognitive Batteries in Patients With Schizophrenia
Study Start Date : December 2007
Primary Completion Date : March 2009
Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1
MATRICS Consensus Cognitive Battery
Other: MATRICS Consensus Cognitive Battery
The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
Other Names:
  • MCCB
Experimental: 2
Cognitive Drug Research Computerized Cognitive Assessment System
Other: CDR Computerized Cognitive Assessment System
Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
Other Name: CDR

Outcome Measures

Primary Outcome Measures :
  1. Test-retest reliabilities of MATRICS Consensus Cognitive Battery (MCCB) and the Cognitive Drug Research (CDR) Computerized Cognitive Assessment System [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Cognitive domains measured by MCCB versus CDR [ Time Frame: 4 weeks ]
  2. Correlation of MCCB versus CDR scores with clinical measures of quality of life [ Time Frame: 4 weeks ]
  3. Self-reported tolerability and satisfaction of the MCCB and CDR assessments [ Time Frame: 4 weeks ]
  4. Practicality of MCCB versus CDR as reported by test administrators [ Time Frame: 4 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women and men aged 18-65 with DSM-IV diagnosis of schizophrenia or schizoaffective disorder (depressed type) by diagnostic interview and chart review.
  2. Clinically stable on a stable dose of antipsychotic medication for at least one month; no current active suicidal ideation.
  3. Not treated with investigational medication in the past 30 days.
  4. Competent to provide informed consent.

Exclusion Criteria:

  1. Diagnosis of dementia, neurodegenerative disease, seizure disorder, current substance abuse or dependence disorders, including alcohol, active within the last 3 months or any Axis I DSM-IV diagnosis other than schizophrenia or schizoaffective disorder (depressed type).
  2. Serious illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease that is not stabilized such that hospitalization for treatment of that illness is likely within the next two months.
  3. Patients who, in the investigator's opinion, pose a current severe homicide or suicide risk.
  4. History of multiple head injuries with neurological sequelae or a single severe head injury with lasting neurological sequelae.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00499044

United States, Massachusetts
Freedom Trail Clinic, Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
North Suffolk Mental Health Association
Principal Investigator: A. Eden Evins, M.D., M.P.H. Massachusetts General Hospital
More Information

Additional Information:
Responsible Party: A. Eden Evins, M.D., M.P.H., Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00499044     History of Changes
Other Study ID Numbers: CORRC #18-2007
First Posted: July 11, 2007    Key Record Dates
Last Update Posted: November 26, 2009
Last Verified: November 2009

Keywords provided by North Suffolk Mental Health Association:

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders